The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation
Open accessAbstract
OBJECTIVES: All complement pathways lead to the formation of C5a, which is believed to contribute to the influx and activation of C5a-receptor (C5aR) bearing cells into the joints of patients with rheumatoid arthritis (RA). Studies in animal models of RA have suggested therapeutic potential of C5aR blockade. In this study, we examined the effects of the C5aR blockade on synovial inflammation in RA patients. METHODS: We performed a double-blind, placebo-controlled study using an orally administered C5aR-antagonist. Twenty-one patients with active RA were randomized 2:1 to treatment with a C5aR-antagonist AcF- (OpdChaWR) (PMX53) vs placebo for 28 days. Serum concentrations of PMX53 were determined. Synovial tissue was obtained at baseline and after 28 days of treatment for pharmacodynamic analysis using immunohistochemistry and digital image analysis. RESULTS: All patients completed the study. Areas under the curve (AUCs) of PMX53 in patients' blood samples showed a mean of 40.8 nmol h/l. There was neither decrease in cell infiltration, nor changes in key biomarkers associated with clinical efficacy after active treatment. In addition, there was no trend towards clinical improvement in the C5aR-antagonist-treated group compared with placebo nor was there a correlation between the AUC and clinical response. CONCLUSIONS: Treatment with PMX53 did not result in a reduction of synovial inflammation despite reaching serum levels of PMX53 that block C5aR-mediated cell activation in vitro. The data suggest that C5aR blockade does not result in reduced synovial inflammation in RA patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Cited by
Interactions between the immune and nervous systems in pain
Ren, K., & Dubner, R. (2010) · Nature Medicine · doi:10.1038/nm.2234 · Cited by 814
New insights into the immune functions of complement
Reis, E. S., Mastellos, D. C., Hajishengallis, G., & Lambris, J. D. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0168-x · Cited by 470
Complement, a target for therapy in inflammatory and degenerative diseases
Morgan, B. P., & Harris, C. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4657 · Cited by 431
STEC-HUS, atypical HUS and TTP are all diseases of complement activation
Noris, M., Mescia, F., & Remuzzi, G. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.195 · Cited by 383
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Metadata
- Authors
- Vergunst, C. E., Gerlag, D. M., Dinant, H., Schulz, L., Vinkenoog, M., Smeets, T. J. M., Sanders, M. E., Reedquist, K. A., & Tak, P. P.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-08-05
- Volume
- 46
- Issue
- 12
- Pages
- 1773-1778
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2137349478
- Cited by
- 163
- References
- 2
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. https://app.cochat.ai/papers/10.1093/rheumatology/kem222
- The paper
- Vergunst, C. E., Gerlag, D. M., Dinant, H., Schulz, L., Vinkenoog, M., Smeets, T. J. M., Sanders, M. E., Reedquist, K. A., & Tak, P. P. (2007). Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology. https://doi.org/10.1093/rheumatology/kem222
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.